Pharmaceuticals

Alpha Mannosidosis Market Forecast 2025–2034: Where Businesses Should Invest Next

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Alpha Mannosidosis Market By 2029?

The alpha mannosidosis market size has shown rapid growth in recent years. It is projected to increase from $15.1 billion in 2024 to $17.87 billion in 2025, achieving a compound annual growth rate (CAGR) of 18.3%. This historical expansion can be attributed to factors such as emerging market development, increasing urbanization, a heightened demand for man-made fibers, and various government initiatives supporting the textile industry.

The alpha mannosidosis market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $33.81 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 17.3%. This growth during the forecast period can be attributed to factors such as global population increases and urbanization, the rise of e-commerce, a growing demand for sportswear, the expanding presence of organized retail in developing economies, and the increasing adoption of social media. Prominent trends observed in the forecast period encompass the heightened utilization of enzyme therapy, the uptake of hematopoietic stem cell transplantation, and the implementation of cisterna magna infusion.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

Which Major Market Drivers Are Shaping The Future Of The Alpha Mannosidosis Market?

The increasing need for precision medicine is anticipated to boost the alpha mannosidosis market. Precision medicine represents a customized healthcare strategy that accounts for patients’ unique genetic makeup, environmental factors, and lifestyle choices to optimize treatment and prevention. The expansion of precision medicine is propelled by innovations in genomic technologies and data analytics, which allow for more precise identification of genetic variations and their health effects. Furthermore, the rising desire for personalized treatment alternatives, coupled with greater recognition of the drawbacks of standardized approaches, has stimulated interest in customized healthcare solutions. Precision medicine aids in developing targeted treatments specifically designed for the genetic mutations and patient profiles linked to this uncommon condition. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit umbrella organization, indicated that in 2023, the FDA sanctioned 16 new personalized treatments for rare diseases, a significant jump from just six approvals in 2022. Consequently, the escalating demand for precision medicine is propelling the alpha mannosidosis market’s growth.

Which Key Segments Fueling The Alpha Mannosidosis Market?

The alpha mannosidosis market covered in this report is segmented –

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Speciality Clinics

Subsegments:

1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT

2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations

3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

What Are The Major Trends Driving The Growth Of The Alpha Mannosidosis Market?

Leading companies in the alpha mannosidosis market are prioritizing the development of enzyme replacement therapy for the uncommon condition of alpha-mannosidosis. This therapeutic approach, by delivering exogenous alpha-mannosidase, helps to diminish the build-up of mannose-rich oligosaccharides in various tissues and organs. Such accumulation is a distinguishing characteristic of alpha-mannosidosis and contributes to its pathological consequences. For example, in February 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, introduced Lamzede (velmanase alfa), the first enzyme replacement therapy sanctioned in the United States for addressing alpha-mannosidosis, a rare genetic disorder marked by an absence of the enzyme alpha-mannosidase in the body, and its manifestations outside of the central nervous system. Lamzede works by mimicking the action of the human body’s alpha-mannosidase enzyme, thereby restoring normal cellular activity in patients. Patients receive an injection of 10 mg of Lamzede once a week.

Which Key Market Players Are Investing In Expansion And Innovation Of Alpha Mannosidosis Market?

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Alpha Mannosidosis Market?

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Alpha Mannosidosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=4093&type=smp

Browse Through More Reports Similar to the Global Alpha Mannosidosis Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Stem Cell Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795